Pharmacogenomics: Social, Ethical, and Clinical Dimensions

Preface.

PART I: INTRODUCTION: SCIENCE AND SOCIETY.

Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).

Pharmacogenomics:  Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).

The Implications of Population Genetics for Pharmacogenomics (C. Hanis).

PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.

Genome Research and Minorities (H. Greely).

Drug Development Strategies (P. Manasco & T. Arledge).

Drug Development,  Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).

Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally,  et al.).

PART III: CLINICAL APPLICATIONS.

Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky).

Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman).

Medical Liability for Pharmacogenomics (L. Palmer).

The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation  (D. Brushwood).

PART IV: THE SOCIAL DIMENSION.

Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). 

 Pharmacogenomics and the Social Construction of Identity (M. Foster).

Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson).

Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson).

PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).

Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein).

Index.